Pertuzumab in combination with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer: safety, efficacy, and progression free survival: breast cancer: basic and clinical research
Tyrosine kinase inhibitors have revolutionized the oncology community and were pioneered by the use in HER2-targeted therapies. Improved outcomes were seen with the advent of trastuzumab, leading investigators to develop newer agents to target the HER2 pathway such as the novel monoclonal antibody p...
Gespeichert in:
| Veröffentlicht in: | Breast cancer : basic and clinical research 2014-05, p.81 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 81 |
| container_title | Breast cancer : basic and clinical research |
| container_volume | |
| creator | Maly, Joseph J Macrae, Erin R |
| description | Tyrosine kinase inhibitors have revolutionized the oncology community and were pioneered by the use in HER2-targeted therapies. Improved outcomes were seen with the advent of trastuzumab, leading investigators to develop newer agents to target the HER2 pathway such as the novel monoclonal antibody pertuzumab. In this paper, we describe the attributes of pertuzumab including: mechanism of action, pharmacokinetics and metabolism, safety/cardiotoxicity, drug interactions, efficacy, and role in HER2-positive breast cancer management. Newly reviewed here versus previously published reviews on pertuzumab oriented therapy are data of pertuzumab monotherapy as it is used in combination with other anti-HER2 agents derived from preclinical research and ongoing clinical trials. MATERIALS AND METHODS: A computer based literature search was carried out using PubMed data reported at international meetings (ASCO) up to September 2013 were included. KEYWORDS: pertuzumab, trastuzumab, HER2, breast cancer |
| doi_str_mv | 10.4137/BCBCR.S9032 |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A369793709</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A369793709</galeid><sourcerecordid>A369793709</sourcerecordid><originalsourceid>FETCH-LOGICAL-g679-3becf254d3ba6a129e322b04938951780493fcbd82581509e18e11ff8ca8a58e3</originalsourceid><addsrcrecordid>eNptkM1OAjEURmehiYiufIEmbh2ctgzTsgOCYkKiQfbkTrmFmpkOaQsGX9MXsuNPYozpol_a75w2N0muaNbrU17cjifjyaL3LDPOTpIOpYVIGeP9s-Tc-5csG1CRyU7y_oQu7N_2NZTEWKKaujQWgmkseTVhS4ID_3MPdk3UFusmbNHB7tgCMcYOQqjRBtJoMpsuWLprvAnmgKTGEPnoU6SMLR-IAqvQDYkHjeF4Q1Bro0DF1Op3rtk49L59XztE4vfuYA5QDf_yJfgo_fxSZWxUVCSCCE5tL5JTDZXHy--9myzvpsvJLJ0_3j9MRvN0MyhkyktUmuX9NS9hAJRJ5IyVWV9yIfM4rTZpVa4FywXNM4lUIKVaCwUCcoG8m1x_aTdQ4cpY3cRhqdp4tRrxgSwkLzIZW71_WnGtsTaqsahNPP8FfACiK461</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pertuzumab in combination with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer: safety, efficacy, and progression free survival: breast cancer: basic and clinical research</title><source>DOAJ Directory of Open Access Journals</source><source>Sage Journals GOLD Open Access 2024</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Maly, Joseph J ; Macrae, Erin R</creator><creatorcontrib>Maly, Joseph J ; Macrae, Erin R</creatorcontrib><description>Tyrosine kinase inhibitors have revolutionized the oncology community and were pioneered by the use in HER2-targeted therapies. Improved outcomes were seen with the advent of trastuzumab, leading investigators to develop newer agents to target the HER2 pathway such as the novel monoclonal antibody pertuzumab. In this paper, we describe the attributes of pertuzumab including: mechanism of action, pharmacokinetics and metabolism, safety/cardiotoxicity, drug interactions, efficacy, and role in HER2-positive breast cancer management. Newly reviewed here versus previously published reviews on pertuzumab oriented therapy are data of pertuzumab monotherapy as it is used in combination with other anti-HER2 agents derived from preclinical research and ongoing clinical trials. MATERIALS AND METHODS: A computer based literature search was carried out using PubMed data reported at international meetings (ASCO) up to September 2013 were included. KEYWORDS: pertuzumab, trastuzumab, HER2, breast cancer</description><identifier>ISSN: 1178-2234</identifier><identifier>DOI: 10.4137/BCBCR.S9032</identifier><language>eng</language><publisher>Sage Publications Ltd. (UK)</publisher><subject>Antimitotic agents ; Antineoplastic agents ; Breast cancer ; Cancer ; Chemotherapy ; Clinical trials ; Development and progression ; Metastasis ; Monoclonal antibodies ; Oncology, Experimental ; Physiological aspects</subject><ispartof>Breast cancer : basic and clinical research, 2014-05, p.81</ispartof><rights>COPYRIGHT 2014 Sage Publications Ltd. (UK)</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Maly, Joseph J</creatorcontrib><creatorcontrib>Macrae, Erin R</creatorcontrib><title>Pertuzumab in combination with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer: safety, efficacy, and progression free survival: breast cancer: basic and clinical research</title><title>Breast cancer : basic and clinical research</title><description>Tyrosine kinase inhibitors have revolutionized the oncology community and were pioneered by the use in HER2-targeted therapies. Improved outcomes were seen with the advent of trastuzumab, leading investigators to develop newer agents to target the HER2 pathway such as the novel monoclonal antibody pertuzumab. In this paper, we describe the attributes of pertuzumab including: mechanism of action, pharmacokinetics and metabolism, safety/cardiotoxicity, drug interactions, efficacy, and role in HER2-positive breast cancer management. Newly reviewed here versus previously published reviews on pertuzumab oriented therapy are data of pertuzumab monotherapy as it is used in combination with other anti-HER2 agents derived from preclinical research and ongoing clinical trials. MATERIALS AND METHODS: A computer based literature search was carried out using PubMed data reported at international meetings (ASCO) up to September 2013 were included. KEYWORDS: pertuzumab, trastuzumab, HER2, breast cancer</description><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Development and progression</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Oncology, Experimental</subject><subject>Physiological aspects</subject><issn>1178-2234</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptkM1OAjEURmehiYiufIEmbh2ctgzTsgOCYkKiQfbkTrmFmpkOaQsGX9MXsuNPYozpol_a75w2N0muaNbrU17cjifjyaL3LDPOTpIOpYVIGeP9s-Tc-5csG1CRyU7y_oQu7N_2NZTEWKKaujQWgmkseTVhS4ID_3MPdk3UFusmbNHB7tgCMcYOQqjRBtJoMpsuWLprvAnmgKTGEPnoU6SMLR-IAqvQDYkHjeF4Q1Bro0DF1Op3rtk49L59XztE4vfuYA5QDf_yJfgo_fxSZWxUVCSCCE5tL5JTDZXHy--9myzvpsvJLJ0_3j9MRvN0MyhkyktUmuX9NS9hAJRJ5IyVWV9yIfM4rTZpVa4FywXNM4lUIKVaCwUCcoG8m1x_aTdQ4cpY3cRhqdp4tRrxgSwkLzIZW71_WnGtsTaqsahNPP8FfACiK461</recordid><startdate>20140512</startdate><enddate>20140512</enddate><creator>Maly, Joseph J</creator><creator>Macrae, Erin R</creator><general>Sage Publications Ltd. (UK)</general><scope/></search><sort><creationdate>20140512</creationdate><title>Pertuzumab in combination with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer: safety, efficacy, and progression free survival: breast cancer: basic and clinical research</title><author>Maly, Joseph J ; Macrae, Erin R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g679-3becf254d3ba6a129e322b04938951780493fcbd82581509e18e11ff8ca8a58e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Development and progression</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Oncology, Experimental</topic><topic>Physiological aspects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maly, Joseph J</creatorcontrib><creatorcontrib>Macrae, Erin R</creatorcontrib><jtitle>Breast cancer : basic and clinical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maly, Joseph J</au><au>Macrae, Erin R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pertuzumab in combination with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer: safety, efficacy, and progression free survival: breast cancer: basic and clinical research</atitle><jtitle>Breast cancer : basic and clinical research</jtitle><date>2014-05-12</date><risdate>2014</risdate><spage>81</spage><pages>81-</pages><issn>1178-2234</issn><abstract>Tyrosine kinase inhibitors have revolutionized the oncology community and were pioneered by the use in HER2-targeted therapies. Improved outcomes were seen with the advent of trastuzumab, leading investigators to develop newer agents to target the HER2 pathway such as the novel monoclonal antibody pertuzumab. In this paper, we describe the attributes of pertuzumab including: mechanism of action, pharmacokinetics and metabolism, safety/cardiotoxicity, drug interactions, efficacy, and role in HER2-positive breast cancer management. Newly reviewed here versus previously published reviews on pertuzumab oriented therapy are data of pertuzumab monotherapy as it is used in combination with other anti-HER2 agents derived from preclinical research and ongoing clinical trials. MATERIALS AND METHODS: A computer based literature search was carried out using PubMed data reported at international meetings (ASCO) up to September 2013 were included. KEYWORDS: pertuzumab, trastuzumab, HER2, breast cancer</abstract><pub>Sage Publications Ltd. (UK)</pub><doi>10.4137/BCBCR.S9032</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-2234 |
| ispartof | Breast cancer : basic and clinical research, 2014-05, p.81 |
| issn | 1178-2234 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A369793709 |
| source | DOAJ Directory of Open Access Journals; Sage Journals GOLD Open Access 2024; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Antimitotic agents Antineoplastic agents Breast cancer Cancer Chemotherapy Clinical trials Development and progression Metastasis Monoclonal antibodies Oncology, Experimental Physiological aspects |
| title | Pertuzumab in combination with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer: safety, efficacy, and progression free survival: breast cancer: basic and clinical research |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T02%3A38%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pertuzumab%20in%20combination%20with%20trastuzumab%20and%20chemotherapy%20in%20the%20treatment%20of%20HER2-positive%20metastatic%20breast%20cancer:%20safety,%20efficacy,%20and%20progression%20free%20survival:%20breast%20cancer:%20basic%20and%20clinical%20research&rft.jtitle=Breast%20cancer%20:%20basic%20and%20clinical%20research&rft.au=Maly,%20Joseph%20J&rft.date=2014-05-12&rft.spage=81&rft.pages=81-&rft.issn=1178-2234&rft_id=info:doi/10.4137/BCBCR.S9032&rft_dat=%3Cgale%3EA369793709%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A369793709&rfr_iscdi=true |